文献速递白血病造血干细胞移植与细胞治疗

对符合异基因移植条件的费城染色体阳性急性淋巴细胞白血病成人患者管理的批判性综述

A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2024-09-17

20%-30%的成人急性淋巴细胞白血病(ALL)患者携带费城染色体(Ph+)。针对BCR::ABL1融合蛋白的酪氨酸激酶抑制剂(TKI)靶向治疗显著改善了预后,但在符合异基因移植条件的患者中仍存在诸多治疗争议。本文综述最新数据并讨论这些争议,包括诱导期最佳TKI选择、多系与淋系亚型的临床相关性、CR1后是否均需移植、无化疗方案能否替代移植、移植前后微小残留病处理、移植后维持TKI及挽救治疗等。

要点

  • 20%-30%成人ALL携带Ph+染色体,TKI靶向BCR::ABL1显著改善预后。
  • 符合异基因移植条件的Ph+ ALL患者存在诱导TKI选择、是否移植等争议。
  • 本文综述最新数据并讨论上述争议以指导当代管理。

核心结论

  • TKI靶向BCR::ABL1融合蛋白显著改善了Ph+ ALL预后,但在符合异基因移植条件的成人患者中仍存在多项治疗争议,本综述讨论最新数据以指导当代管理。

研究设计与样本

  • 本文为批判性综述,汇总影响Ph+ ALL当代管理的最新数据并讨论相关争议。

主要发现

  • 历史上Ph+ ALL预后显著较差,无移植物时长期生存不常见。
  • 针对BCR::ABL1融合蛋白的TKI靶向治疗显著改善了预后。
  • 诱导期最佳TKI选择、多系与淋系亚型的临床相关性、CR1后是否均需移植、无化疗方案能否替代移植、移植前后MRD处理、移植后维持TKI及挽救治疗等均为待解决的争议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute lymphoblastic leukaemia (ALL) in 20%-30% of adult patients contains the Philadelphia (Ph+) chromosome. Historically, Ph+ ALL denoted a markedly inferior outcome and long-term survival in the absence of an allograft was uncommon. However, the advent of targeted therapy directed against the BCR::ABL1 fusion protein with various tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis, resulting in a number of treatment controversies in allograft-eligible patients. Which is the best TKI to use in induction? What is the clinical relevance of the subdivision of Ph+ ALL into multilineage vs lymphoid types? Do all patients in first morphological complete remission (CR1) after induction and consolidation with chemotherapy/TKI require an allograft? If not, what risk factors predict a poor outcome without an allograft? Can chemotherapy-free approaches, such as blinatumomab in conjunction with more potent TKIs, obviate the need for an allograft in high-risk patients? What is the best strategy to deal with persistent or emerging minimal residual disease both pre- and post-transplant? Is maintenance TKI indicated in all patients post allograft? Can salvage therapy and a subsequent allograft cure patients who relapse after not being transplanted in CR1? This manuscript reviews the latest data influencing contemporary management and discusses these controversies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shanmuganathan N, Grigg A. A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia. Br J Haematol. 2024. PMID: 39289867. doi:10.1111/bjh.19682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。